NCT02949388 - Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

199

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

December 31, 2017

Conditions

Chronic Stable Plaque Psoriasis

Interventions

DRUG

Placebo

Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart

DRUG

400 mg (200 mg BID)

Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart

DRUG

300 mg (150 mg BID)

Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart

Trial Locations (34)

10012

Clinical Study Site, New York

22911

Study Center, Charlottesville

31406

Study Site, Savannah

32127

Study Site, Port Orange

33609

Clinical Study Site, Tampa

40217

Study Site, Louisville

46617

Clinical Study Site, South Bend

48038

Clinical Study Site, Clinton Township

48346

Clinical Study Site, Clarkston

60005

Study Center, Arlington Heights

63117

Clinical Study Site, St Louis

66215

Study Center, Overland Park

71913

Study Center, Hot Springs

72758

Clinical Study Site, Rogers

77004

Clinical Study Site, Houston

77598

Study Site, Webster

78213

Clinical Study Site, San Antonio

78229

Clinical Study Site, San Antonio

Study Site, San Antonio

78660

Clinical Study Site, Pflugerville

78759

Study Center, Austin

80209

Study Site, Denver

80210

Clinical Study Site, Denver

85308

Study Site, Glendale

89106

Study Site, Las Vegas

90017

Study Center, Los Angeles

90036

Study Site, Los Angeles

91403

Study Site, Sherman Oaks

92056

Clinical Study Site, Oceanside

92562

Clinical Study Site, Murrieta

97210

Clinical Study Site, Portland

03801

Clinical Study Site, Portsmouth

08009

Clinical Study Site, Berlin

02919

Study Site, Johnston